Indian ATMP (Advanced Therapy Medicinal Products) Manufacturing MEP — EU EMA 1394/2007 + USFDA 21 CFR 1271 + Schedule M
A 10,000 m² Indian multi-product ATMP facility (MSC + tissue-engineered + CAR-T) demands ₹1,545 Cr MEP capex with MCB vault + WCB suite + bioreactor + Grade A in B fill + tissue scaffold fab + QC lab + cryopreservation + LIMS + segregated HVAC. EU EMA 1394/2007 + USFDA 21 CFR 1271 + Schedule M + ICH Q5 + ISCT + FACT-JACIE + WHO TRS 1019 + India RCGM govern. ATMP regulatory pathway 96 months concept-to-commercial. Three failures: single-use vs multi-use system selection not analysed, MCB vault security inadequate (shared vault) blocking IND filing, tissue-engineered biomaterial regulatory pathway not aligned to USFDA 21 CFR 1271 + EU MDR + CDSCO.
Indian ATMP manufacturing framework
Indian ATMP (Advanced Therapy Medicinal Products) — Mesenchymal stem cell (MSC) therapy + tissue-engineered products + biologic implants + Engineered T-cell. India players — Stempeutics + Reliance Life Sciences + Cellsure + Stemfit + Eyestem. Standards stack — EU EMA ATMP Regulation 1394/2007 + USFDA 21 CFR 1271 + Schedule M 2023 + ICH Q5A + ISCT (International Society for Cell + Gene Therapy) + FACT-JACIE + WHO TRS 1019 + India RCGM Stem Cell Guidelines 2017 updates 2024.
Multi-product ATMP (MSC + Tissue-engineered + CAR-T) MEP scope — 10,000 m²
| Zone | Grade | Function | Capex (₹ Cr) |
|---|---|---|---|
| Master cell bank vault | — | controlled access + -150°C | 85 |
| Working cell bank suite | C/B | — | 125 |
| Cell expansion bioreactor (10-100 L) | C | — | 185 |
| Cell harvesting + downstream | B | centrifuge + filtration | 125 |
| Formulation + fill (Grade A in B) | A in B | — | 185 |
| Tissue-engineered scaffold fab | C | 3D bioprinter + biomaterial | 125 |
| Quality control lab (sterility + cell-viability + potency + endotoxin) | — | USP 1116 + ICH Q5 | 185 |
| Cryopreservation suite (-196°C controlled-rate) | — | vapour-phase LN2 | 85 |
| Decontamination + waste | — | VHP + autoclave + incinerate | 45 |
| HVAC + AHU (segregated Grade A/B/C/D) | — | — | 220 |
| Pure utilities (WFI + pure steam + medical N2 + CO2) | — | — | 125 |
| LIMS + GMP electronic records | — | 21 CFR Part 11 | 55 |
| Total ATMP facility | — | — | 1,545 |
Three Indian ATMP manufacturing MEP failures
- Single-use vs multi-use system selection not analysed — ATMP allows both — single-use cuts cross-contamination risk but adds plastic waste + cost. Multi-use needs full CIP + SIP validation per batch + 21 CFR 211. Indian sites default to multi-use without proper validation — face USFDA cGMP issues.
- Master cell bank vault security inadequate — MCB is the irreplaceable foundation. Requires biometric access + redundant cryostorage + monitored alarm + insurance documentation. Indian R&D facilities sometimes have shared vault — face IND/NDA filing rejection.
- Tissue-engineered scaffold biomaterial regulatory pathway not aligned — collagen + decellularised matrix + biomaterials must comply with USFDA 21 CFR 1271 + EU MDR + India CDSCO Medical Device classification. Indian R&D sometimes lacks clarity + faces commercial pathway delay.
- EU EMA ATMP Regulation 1394/2007 + ATMP Guideline 2018.
- USFDA 21 CFR 1271 + Guidance for Industry on Cellular + Gene Therapy 2024.
- Schedule M 2023 + India CDSCO Stem Cell + ATMP Guidelines 2024.
- ICH Q5A + Q5D + Q5E — Viral Safety + Cell Banks + Comparability.
- ISCT International Society for Cell + Gene Therapy Standards 2024.
- FACT-JACIE Cell Therapy Accreditation Standards 2024.
- WHO TRS 1019 Annex 4 — ATMP.
- India RCGM + DBT Stem Cell Guidelines 2017 + 2024 amendments.